tetano
Editor, Senior Moderator
PLoS One. 2016 Nov 4;11(11):e0165384. doi: 10.1371/journal.pone.0165384. eCollection 2016.
[h=1]Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults.[/h] Lazarus R[SUP]1[/SUP], Kelly S[SUP]1[/SUP], Snape MD[SUP]1[/SUP], Vandermeulen C[SUP]2,[/SUP][SUP]3[/SUP], Voysey M[SUP]4[/SUP], Hoppenbrouwers K[SUP]2[/SUP], Hens A[SUP]5[/SUP], Van Damme P[SUP]5[/SUP], Pepin S[SUP]6[/SUP], Leroux-Roels I[SUP]7[/SUP], Leroux-Roels G[SUP]7[/SUP], Pollard AJ[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Avian influenza continues to circulate and remains a global health threat not least because of the associated high mortality. In this study antibody persistence, booster vaccine response and cross-clade immune response between two influenza A(H5N1) vaccines were compared. Participants aged over 18-years who had previously been immunized with a clade 1, A/Vietnam vaccine were re-immunized at 6-months with 7.5 μg of the homologous strain or at 22-months with a clade 2, alum-adjuvanted, A/Indonesia vaccine. Blood sampled at 6, 15 and 22-months after the primary course was used to assess antibody persistence. Antibody concentrations 6-months after primary immunisation with either A/Vietnam vaccine 30 μg alum-adjuvanted vaccine or 7.5 μg dose vaccine were lower than 21-days after the primary course and waned further with time. Re-immunization with the clade 2, 30 μg alum-adjuvanted vaccine confirmed cross-clade reactogenicity. Antibody cross-reactivity between A(H5N1) clades suggests that in principle a prime-boost vaccination strategy may provide both early protection at the start of a pandemic and improved antibody responses to specific vaccination once available.
[h=4]TRIAL REGISTRATION:[/h] ClinicalTrials.gov NCT00415129.
PMID: 27814377 DOI: 10.1371/journal.pone.0165384
[PubMed - in process]
[h=1]Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults.[/h] Lazarus R[SUP]1[/SUP], Kelly S[SUP]1[/SUP], Snape MD[SUP]1[/SUP], Vandermeulen C[SUP]2,[/SUP][SUP]3[/SUP], Voysey M[SUP]4[/SUP], Hoppenbrouwers K[SUP]2[/SUP], Hens A[SUP]5[/SUP], Van Damme P[SUP]5[/SUP], Pepin S[SUP]6[/SUP], Leroux-Roels I[SUP]7[/SUP], Leroux-Roels G[SUP]7[/SUP], Pollard AJ[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Avian influenza continues to circulate and remains a global health threat not least because of the associated high mortality. In this study antibody persistence, booster vaccine response and cross-clade immune response between two influenza A(H5N1) vaccines were compared. Participants aged over 18-years who had previously been immunized with a clade 1, A/Vietnam vaccine were re-immunized at 6-months with 7.5 μg of the homologous strain or at 22-months with a clade 2, alum-adjuvanted, A/Indonesia vaccine. Blood sampled at 6, 15 and 22-months after the primary course was used to assess antibody persistence. Antibody concentrations 6-months after primary immunisation with either A/Vietnam vaccine 30 μg alum-adjuvanted vaccine or 7.5 μg dose vaccine were lower than 21-days after the primary course and waned further with time. Re-immunization with the clade 2, 30 μg alum-adjuvanted vaccine confirmed cross-clade reactogenicity. Antibody cross-reactivity between A(H5N1) clades suggests that in principle a prime-boost vaccination strategy may provide both early protection at the start of a pandemic and improved antibody responses to specific vaccination once available.
[h=4]TRIAL REGISTRATION:[/h] ClinicalTrials.gov NCT00415129.
PMID: 27814377 DOI: 10.1371/journal.pone.0165384
[PubMed - in process]